Marc H. Hedrick, M.D.
25,000
Purchased private placement shares, Series A and Series B warrants in the May 2024 PIPE Financing.
With the Company
Open in proxy
| Officer | Age | In this role | Joined | Pay | Source |
|---|---|---|---|---|---|
|
Marc H. Hedrick, M.D.
Also a director
Chief Executive Officer, President and Director
|
64 | Not stated | Not stated | Not reported | |
|
Andrew Sims
Chief Financial Officer
|
53 |
Since 2020
6 years
|
2020 | Not reported | |
|
Eric Joseph Daniels
Chief Development Officer
Title from the Form 4 dated Apr 20, 2026
|
Not stated | Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Purchased private placement shares, Series A and Series B warrants in the May 2024 PIPE Financing.
Purchased private placement shares, Series A and Series B warrants in the May 2024 PIPE Financing.
Purchased private placement shares, Series A and Series B warrants in the May 2024 PIPE Financing.
Purchased private placement shares, Series A and Series B warrants in the May 2024 PIPE Financing.
Purchased private placement shares, Series A and Series B warrants in the May 2024 PIPE Financing.
Purchased private placement shares, Series A and Series B warrants in the May 2024 PIPE Financing.
Loan to the Company under a promissory note, fully repaid in March 2025.
Loading...
